Neurocrine to Buy Soleno for Treatment for Rare Disease That Causes Relentless Hunger

1 hour ago 1

Neurocrine agreed to wage $53 a stock successful currency for Soleno.

Neurocrine Biosciences agreed to bargain Soleno Therapeutics for $2.9 billion, giving it the archetypal approved attraction for a uncommon familial upset that causes relentless, life-threatening hunger.

The acquisition centers connected Soleno’s attraction for Prader-Willi syndrome, a uncommon familial upset that affects astir 10,000 radical successful the U.S. People with the information acquisition an unrelenting, compulsive hunger that tin thrust them to devour until they endure obesity, diabetes oregon life-threatening consequences similar tummy rupture.

An Inside Look astatine OpenAI and Anthropic’s Finances Ahead of Their IPOs
Gulf Funds Agree to Back Paramount’s $81 Billion Takeover of Warner
The Wall Street Dealmaker Charged With Solving Paul Weiss’s Identity Crisis
‘I Will Destroy You’: The Battle Inside a Midwestern Media Dynasty
One of the Stock Market’s Last Havens Is Now astatine Risk

Soleno’s treatment, called Vykat XR, won FDA support successful March 2025 arsenic the archetypal and lone attraction for the condition. It generated $190 cardinal successful gross successful its archetypal twelvemonth connected the market.

Neurocrine agreed to wage $53 a stock successful cash, a astir 34% premium to Soleno’s closing stock terms connected April 2. The transaction volition beryllium funded with currency connected hand, but Neurocrine said it plans to instrumentality connected immoderate caller debt. It is expected to adjacent by aboriginal July.

Soleno shares roseate 32% successful greeting trading. Neurocrine’s banal fell astir 1.5%.

Neurocrine’s main executive, Kyle Gano, said absorption volition leverage “our acquisition and capabilities to grow VYKAT XR’s scope to payment much patients.”

For Neurocrine, the woody adds a 3rd marketed medicine to a portfolio anchored by Ingrezza, its attraction for involuntary musculus movements that generated $2.51 cardinal successful gross past year.

The San Diego-based institution has been gathering retired its rare-disease concern since precocious 2024, erstwhile it won support for Crenessity, a attraction for a hormone upset affecting the adrenal glands that brought successful $301 cardinal past year.

Vykat XR’s patents are expected to support competitors from selling a rival mentation until the mid-2040s, according to Neurocrine.

The woody is the latest successful a engaged twelvemonth for dealmaking successful the biotech industry. In the archetypal quarter, biotechs and pharmaceutical companies inked $68.6 cardinal successful deals, according to information supplier LSEG.

Write to Nicholas G. Miller astatine [email protected] and Xavier Martinez astatine [email protected]

Pain astatine the Pump Should Mean Pain successful the Economy, Not Higher Rates
The U.S. Plastics Industry Was successful the Doldrums. Then the Iran War Began.
PepsiCo, Diageo Drop Sponsorship of Kanye West-Headlined U.K. Music Festival
‘Super Mario’ Sequel Scores Year’s Biggest Movie Opening
Oil Mixed, Government Bonds Fall arsenic Trump Steps Up Threats Against Iran

Read Entire Article